白细胞介素18对银屑病T细胞趋化因子受体7表达调控的研究
|
摘要
银屑病(Psoriasis)是一种病情顽固、易反复、治疗困难的常见皮肤病，严重影响着大约1-3％的世界人口的日常生活和心理健康。尽管其确切病因尚不完全清楚，但目前越来越多的证据表明，CD4(+)T细胞的活化是银屑病免疫学发病机制的中心环节。近年来关于其发病机制比较一致的观点是：银屑病的发病有其自身的遗传因素，在受到外界环境的影响后(包括感染、精神等因素)就会促使T细胞及角质形成细胞释放各种细胞因子，引起角质形成细胞的高度增殖及各种炎细胞的浸润，最终表现出银屑病特有的临床及病理特征。白细胞介素18(interleukin-18，IL-18)是一种重要的炎症前因子，主要参与Th1反应，可以介导免疫细胞进入组织而具有潜在的免疫调节作用。目前对于银屑病发病中效应机制的观点已经有了转变，现在认为局部皮损中各种免疫活性细胞、细胞因子和趋化因子及其受体组成的网络引发了一系列相互关联的作用，最
Psoriasis is a common dermatological disorder, affecting approximately 1% to 3% of the general population. Although the pathogenesis of the disease has not been definitively understood, recent evidence suggests that activated CD4-positive helper T-lymphocytes of the Thl phenotype play an important role in the progression of psoriasis. The pathogenesis of psoriasis is linked to the activation of several types of leucocytes that control cellular immunity, and to a T-cell-dependent inflammatory process in skin that accelerates the growth of epidermal and vascular cells in psoriasis lesions. The most important processes in immunological activation are Langerhans and T cell activation, differentiation and expression of type 1 T (Thl) cells, selective trafficking of activated T cells to skin, and induction of an inflammatory cytokine and chemokine cascade in skin lesions. Psoriasis is associated with an overexpression of pro-inflammatory cytokines produced by Thl cells and a relative underexpression of Th2 cytokines. The Thl differentiation was found in both lesional areas and in the peripheral blood, although the high production of Thl cytokines or low production of Th2 cytokines is not determined by a genotype at this time. Interleukin-18 (IL-18), also called interferon-gamma (IFN- γ )-inducing factor, is a novel cytokine that plays an important role in the Thl response and a potent role in immunoregulation by
Psoriasis is a common dermatological disorder, affecting approximately 1% to 3% of the general population. Although the pathogenesis of the disease has not been definitively understood, recent evidence suggests that activated CD4-positive helper T-lymphocytes of the Thl phenotype play an important role in the progression of psoriasis. The pathogenesis of psoriasis is linked to the activation of several types of leucocytes that control cellular immunity, and to a T-cell-dependent inflammatory process in skin that accelerates the growth of epidermal and vascular cells in psoriasis lesions. The most important processes in immunological activation are Langerhans and T cell activation, differentiation and expression of type 1 T (Thl) cells, selective trafficking of activated T cells to skin, and induction of an inflammatory cytokine and chemokine cascade in skin lesions. Psoriasis is associated with an overexpression of pro-inflammatory cytokines produced by Thl cells and a relative underexpression of Th2 cytokines. The Thl differentiation was found in both lesional areas and in the peripheral blood, although the high production of Thl cytokines or low production of Th2 cytokines is not determined by a genotype at this time. Interleukin-18 (IL-18), also called interferon-gamma (IFN- γ )-inducing factor, is a novel cytokine that plays an important role in the Thl response and a potent role in immunoregulation by
引文
1. de Korte J, Van Onselen J, Kownacki S, Sprangers MA, Bos JD. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J Eur Acad Dermatol Venereol. 2005, 19(1): 35-41.
2. Griffiths CE. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol. 2003, 17(Suppl 2): 1-5.
3. Zhang XJ, Zhang AP, Yang S, Gao M, Wei SC, He PP, Wang HY, Song YX, Cui Y, Chen JJ. Association of HLA class I alleles with psoriasis vulgaris in southeastern Chinese Hans. J Dermatol Sci. 2003, 33(1): 1-6.
4. Fatma OS, Sarper DA, Dilek E, Emel OA, Semra A, Dilek KS, Mahmut C. HLA-DRB1 association in Turkish psoriasis vulgaris patients. Swiss Med Wkly. 2003, 133(39-40): 541-543.
5. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004, 135(1): 1-8.
6. Lin WJ, Norris DA, Achziger M, Kotzin BL, Tomkinson B. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol. 2001, 117(6): 1546-1553.
7. Onuma S. Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J Dermatol. 1994, 21(4): 223-232.
8. The European FK506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind placebo-controlled study. Arch. Dermatol. 1996, 132(4): 419-423.
9. Servitje O, Bordas X, Seron D, Vidaller A, Moreno A, Curco N, Sais G, Peyri J. Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy. J Cutan Pathol. 1996, 23(5): 431-436.
10. Abu-Elmagd K, Van Thiel D, Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Thomson AW, Starzl TE. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc. 1991, 23(6): 3322-3324.
11. Morel P, Revillard J P, Nicolas J F, Wijdenes J, Rizova H, Thivolet J. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun. 1992, 5(4): 465-477.
12. Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GB, Solvsten H, Ibsen HH, Knudsen L, Jensen P, Petersen JH, Menne T, Baadsgaard O. HuMaxCD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol. 2003, 139(11): 1433-1439.
13. Gottlieb AB, Lebwohl M, Shirin S. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose. placebo-controlled study. J Am Acad Dermatol. 2000, 43(4): 595-604.
14. Chamian F, Lowes MA, Lin SL. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005, 102(6): 2075-2080.
15. Leonardi CL, Papp KA, Gordon KB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005, 52(3 Pt 1): 425-433.
16. Terry W, Barker J, Boehncke WH. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004, 151(Suppl 69): 3-17.
17. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, Plewig G. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol. 1994, 24(3): 593-598.
18. Bata CZ, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest. 1995, 95(1): 317-327.
19. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996, 98(8): 1878-1888.
20. Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AW, Tak PP, Bos JD, Teunissen MB. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res. 2004, 295(11): 465-473.
21. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003, 17(Suppl 2): 12-16.
22. Ellis CN, Krueger GG. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001, 345(4): 248-255.
23. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993, 101(5): 701-705.
24. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. T cells involved in psoriasis vulgaris belong to the Th 1 subset. J Invest Dermatol. 1994, 102(1): 145-149.
25. Romagnani S. Biology of human Th1 and Th2 cells. J Clin Immunol. 1995, 15(3): 21-129.
26. Dinarllo CA. IL-I: A Thl-inducing, Proinflammatory cytokine and new member of the IL-1 family. J AIlergy Clin lmmunol. 1999, 103(1 Pt 1): 11-24.
27. Puren A J, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFN- ν inducing factor) induces IL-1 13 and IL-8 via TNF-α production from non-CD14+ human blood mononuclear. J Clin Invest. 1998, 101(3): 711-721.
28. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995, 378 (6552): 88-91.
29. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H, Kurimoto M. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the bioligic activities of the protein. J Immunol. 1996, 156(11): 4274-4279.
30. Bazan JF, Timans J, Kastelein RA. A newly defined interleukin-1γ. Nature, 1996, 379(6566): 591-594.
31. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, Kurimoto M, Tanimoto T, Flavell RA, Sato V, t-larding MW, Livingston DJ, Su MS. Activation of interferon-gamma inlducing factor mediated by interleukin-lbeta converting enzyme. Science. 1997, 275(5297): 206-209.
32. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, Dinarello CA. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 1997, 386(6625): 619-623.
33. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T, Murakami T. Sanou O, Kojima H, Fujii M, Ohta T, Ikeda M, Ikegami H, Kurimoto M. Purification and characterization of the human interleukin-18 receptor. J Biol Chem. 1997, 272(41): 25737-25742.
34. Kim SH, Reznikov LL, Stuyt RJ, Selzman CH, Fantuzzi G, Hoshino T, Young HA, Dinarello CA. Functional reconstituution and regulation of IL-18 activity by the IL-18R beta chain. J lmmunol. 2001, 166(1): 148-154.
35. Gutzmer R, Langer K, Mommert S, Wittmann M, Kapp A, Werfel T. Human Dendritic Cells Express the IL-18R and Are Chemoattracted to IL-18. J Immunol. 2003, 171(12): 6363-6371.
36. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998, 161(7): 3400-3407.
37. Sareneva T, Julkunen I, Matikainen S. IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J Immunol. 2000, 165(4): 1933-1938.38. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit. AcPL, required for interleukin-18 signaling. J Biol Chem. 1998, 273(45): 29445-29450.
39. Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakanishi K, Takeda Y. Akira S. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 bianding receptor. J lmmunol. 1999. 162(9): 5041-5044.
40. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, Dinarello CA. Structural requirements of six naturally occurring isoforms of the IL-18 banding protein to inhibit IL-18. Proc Natl Acad Sci U S A. 2000, 97(3): 1190-1195.
41. Mee JB, Algm Y, Groves RW. Human keratinocytes constitutively produce but not process interleukin-18. Br J Dermatol. 2000, 143(2): 330-336.
42. Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, Caughman SW. Human keratinocytes constitutivelly express interleukin-18 and secrete biological active interleukin-18 afte treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Derrnatol. 1999, 113(5): 766-772.
43. Taniguchi M, Nagaoka K, Kunikata T, Kayano T, Yamauchi H, Nakamura S, Ikeda M, Orita K, Kurimoto M. Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. JPN J Cancer Res. 1998, 89(10): 1041-1046.
44. Taniguchi M, Nagaoka K, Kunikata T, Kayano T, Yamauchi H, Nakamura S. Ikeda M, Orita K, Kurimoto M. Characterization of anti-human interleukin-18 (IL-18)/interferon-gamma-inducing factor (IGIF) monoclonal antibodies and their application in the measurement of human IL-18 by ELISA. J Immunol Methods. 1997, 206(1-2): 107-113.
45. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murtine T helper 1 cells. Cell Immunol. 1996, 173(2): 230-235.
46. Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, Ikeda M, Kurimoto M. IFN-gamma-inducing factor (IGIF) is a costimulatory facto on the activation of Thl but not Th2 cells and exert its effect independently of IL-12. J Immunol. 1997, 158(4): 1541-1550.
47. Leung BP, Mclnnes IB, Esfandiari E, Wei XQ, Liew FY. Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol. 2000, 164(12): 6495-6502.
48. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Tht and Th2 responses, Annu Rev Immunol. 2001, 19: 423-474.
49. Rothe H, Hausmann A, Casteels K, Okamura H, Kurimoto M, Burkart V, Mathieu C, Kolb H. IL-18 inhibits diabetes development in nonobese diabetic mice by??counterregulation of Th1-dependent destructive insulitis. J Immunol. 1999. 163(3): 1230-1236.
50. Wild JS, Sigounas A, Sur N, Siddiqui MS, Alam R, Kurimoto M, Sur S. IFN-gamma-inducing factor (IL-18) inceases allergic sensitization, serum IgE. Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol. 2000, 164(5): 2701-2710.
51. Leite-De-Moraes MC, Hameg A, Pacilio M, Koezuka Y, Taniguchi M, Van Kaer L. Schneider E, Dy M, Herbelin A. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J Immunol. 2000, 166(2): 945-951.
52. Sugimoto T, Ishikawa Y, Yoshimoto T, Hayashi N, Fujimoto J, Nakanishi K. Interleukin 18 Acts on Memory T Helper Cells Type 1 to Induce Airway Inflammation and Hyperresponsiveness in a Naive Host Mouse. J Exp Med. 2004. 199(4): 535-545.
53. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000, 12(1): 59-63.
54. Koizumi H, Sato-Matsumura KC, Nakamura H, Shida K, Kikkawa S, Matsumoto M, Toyoshima K, Seya T. Distribution of IL-18 and IL-18 receptor in human skin: various forms of IL-18 are produced in keratinocytes. Arch Dermatol Res. 2001. 293(7): 325-333.
55. Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis. Arch Demeratol Res. 2001, 293(7): 334—342.
56. Pietrzak A, Lecewicz-Torun B, Chodorowska G, Rolinski J. Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score. Acta Derm Venereol. 2003, 83(4): 262-265.
57. Gangemi S, Merendino RA, Guarneri F, Minciullo PL, DiLorenzo G, Pacor M. Cannavo SP. Serum levels of interleukin-18 and s-ICAM-I in patients affected by psoriasis: Preliminary considerations. J Eur Acad Dermatol Venereol. 2003, 17(1): 42-46.
58. Wittmann M, Purwar R, Hartmann C, Gutzmer R, Werfel T. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. J Invest Dermatol. 2005, 124(6): 1225-1233.
59. Companjen A, van der Wel L, van der Fits L, Laman J, Prens E. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. Eur Cytokine Netw. 2004, 15(3): 210-216.
60. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18banding prptein: a novel modulator of the cytokine response. Immunity. 1999, 10(1): 127-136.61. Kojima H, Takeuchi M, Ohta T, Nishida Y, Arai N, Ikeda M, Ikegami H. Kurimoto M. IGIF does not drive Thl development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity. 1997, 7(4): 571-581.
62. Kojima H, Takeuchi M, Ohta T, Nishida Y, Arai N, Ikeda M, Ikegami H, Kurimoto M. Interleukin-18 activates the IRAK-TRAF6 pathway in mouse IL-14 cells. Biochem Biophys Res Commun. 1998, 244(1): 183-186.
63. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity. 1998, 9(1): 143-150.
64. Barbulescu K, Becker C, Schlaak JF, Schmitt E, Meyer zum Buschenfelde KH, Neurath MF. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Imnunol. 1998, 160(8): 3642-3647.
65. Shapiro L, Puren A J, Barton HA, Novick D, Peskind RL, Shenkar R, Gu Y, Su MS, Dinarello CA. Interleukin-18 stimulates production of human immunodeficiency virus in the U1 monocytic cell line. Proc Natl Acad Sci USA. 1998, 95(21): 12550-12555.
66. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000, 406(6797): 782-787.
67. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000, 343(5): 338-344.
68. Park H J, Kim H J, Lee JH, Lee JY, Cho BK, Kang JS, Kang H, Yang Y, Cho DH. Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. J Invest Dermatol. 2005, 124(4): 751-755.
69. Ariel A, Novick D, Rubinstein M, Dinarello CA, Lider O, Hershkoviz R. IL-12 and IL-18 induce MAP kinase-dependent adhesion of T cells to extracellular matrix components. J Leukoc Biol. 2002, 72(1): 192-198.
70. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 1999, 11 (11): 822-830.
71. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999, 401 (6754): 708-712.
72. Hagmann M. Memory T cells don't need practice. Science. 1999, 286(5443): 1267-1268.
73. Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science. 1999, 286(5443): 1377-1381.
74. Tough DF, Sun S, Zhang X, Sprent J. Stimulation of memory T cells by cytokines. Vaccine. 2000, 18(16): 1642-1648.75. Tanchot C, Rocha B. The organization of mature T-cell pools, Immunol Today. 1998, 19(12): 575-579.
76. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven Proliferation and Differentiation of Human Naive, Central Memory, and Effector Memory CD4+ T Cells. J Exp Med. 2001, 194(12): 1711-1720.
77. Kohout TA, Nicholas SL, Perry S J, Reinhart G, Junger S, Struthers RS. Differential desensitization, receptor phosphorylation, arrestin recruitment and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem. 2004, 279(22): 23214-23222.
78. Rollins BJ. Chemokines. Blood. 1997, 90(3): 909-928.
79. Murphy PM, Baggiolini M, Charo IF, Herbert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000, 52(2): 145-176.
80. James JC, Kristine EM, Eric JK, Christopher EB, Dulce S, Zhimin S, Judie B, Harry BG, Mark AV, Stuart BG, Mark CG, Andrew JW, Eugene CB, Lijun W. CCR7 Expression and Memory T Cell Diversity in Humans. J Immunol. 2001, 166(2): 877-884.
81. MacLennan IC, Gulbranson-Judge A, Toellner KM, Casamayor-Palleja M, Chan E, Sze DM, Luther SA, Orbea HA. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev. 1997, 156: 53-66.
82. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 1998, 281 (5373): 96-99.
83. Nanki T, Lipsky PE. Cytokine, activation marker, and chemokine receptor expression by individual CD4(+) memory T cells in rheumatoid arthritis synovium. Arthritis Res. 2000, 2(5): 415-423.
84. Von Andrian UH, Mackay CR. T cell function and migration. Two sides of the same coin. N Engl J Medical. 2000, 343(14): 1020-1034.
85. Campbell DJ, Debes GF, Johnston B, Wilson E, Butcher EC. Targeting T cell responses by selective chemokine receptor expression. Semin. Immunol. 2003, 15(5): 277-286.
86. Gudrun FD, Kerstin B, Thorsten W, Ute K, Stefan K, Thomas K, Alf H. CC chemokine receptor 7 expression by effector/memory CD4+ T Cells depends on antigen specificity and tissue localization during influenza a virus infection. J Virol. 78(14): 7528-7535.
87. Sebastiani S, Albanesi C, D'Pita O, Puddu P, Cavani A, Girolomoni G. The role chemokines in allergic contact dermatitis. Arch Dermatol Res. 2002, 293(11): 552-559.
88. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med. 1999, 189(3): 447-450.
89. Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai T, Yoshie O. Fractalkine (CX3CLI) as an amplification circuit of polarized Th1 responses. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem. 1998, 273(12): 7118-7122.
90. Nagira M, Imai T, Hieshima K, Kusuda J, Ridanpaa M, Takagi S, Nishimura M, Kakizaki M, Nomiyama H, Yoshie O. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13. J Biol Chem. 1997, 272(31): 19518-19524.
91. James CL, Robert KC, Youjin L, Hyung-Sik K, Yang W, Joel VW, Theresa B, Carl FW, Guido F, Yang-Xin F. Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J Clin Invest. 2003, 112(10): 1495-1505.
92. Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, Kitaura M, Nishimura M. Kakizaki M, Nomiyama H, Yoshie O. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem. 1997, 272(21): 13803-13809.
93. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA. 1998. 95(1): 258-263.
94. Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT. Nakano H. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med. 1999, 189(3): 451-460.
95. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999, 99(1): 23-33.
96. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol. 2002, 80(5): 497-505.
97. Noelia SS, Lorena RB, Gonzalo de la R, Amaya PK, Julio GB, Daniel M, Natividad L, Antonio C, Carlos C, Angel LC, Paloma SM, José Luis RF. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood. 2004, 104(3): 619-625.
98. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC, Laudanna C. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol. 1999, 162(5): 2472-2475.
99. Lars O, Mariette M, Niklas C, Gabriele H, Ziba K, (?) Z, Thomas B, Golo H. Reinhold F. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 2004, 21(2): 279-288.
100. Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, Lotze MT. Tahara H. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 2000, 60(8): 2209-2217.
101. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC, Laudanna C. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity. 2000, 13(6): 759-769.
102. Sallusto F, Mackay CF, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000, 18:593-620.
103. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Differential expression of chenmokine receptors and chemotactic responsiveness of type 1 T help cells (Thls) and Th2. J Exp Med. 1998, 187(1): 129-134.
104. D'Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Mantovani A. Sinigaglia F. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol. 1998, 161(10): 5111-5115.
105. Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, Girolomoni G. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune reponses. J Invest Dermatol. 2000, 114(2): 295-302.
106. Sebastiani S, Allavena P, Albanesi C, Nasorri F, Bianchi G, Traidl C, Sozzani S. Girolomoni G, Cavani A. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol. 2001, 116(2): 996-1002.
107. Sallusto F, Danielle L, Charles RM, Antonio L. Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes. J. Exp. Med. 1998, 187(6): 875-883.
108. Okada N, Mort N, Koretomo R, Okada Y, Nakayama T, Yoshie O, Mizuguchi H. Hayakawa T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005, 12(2): 129-139.
109. Chuntharapai A, Lee J, Hebert CA, Kim KJ. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol. 1994, 153(12): 5682-5688.
110. Beljaards RC, Van Beck P, Nieboer C, Stoof TJ, Boorsma DM. The expression of interleukin-8 receptor in untreated and treated psoriasis. Arch Dermatol Res. 1997, 289(8): 440-443.
111. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 2001, 81(3): 335-347.
112. Wakugawa M, Nakamura K, Kakinuma T, Onai N, Matsushima K, Tamak K: CC chemokine receptor 4 expression on peripheral blood CD4C T cells reflects disease activity of atopic dermatitis. J Invest Dermatol. 2001, 117(2): 188-196.
113. Makoto Inaoki, Shinichi Sato, Fumiaki Shirasaki, Naofumi Mukaida, Kazuhiko Takehara. The frequency of type 2 CD8+ T cells is increased in peripheral blood from patients with psoriasis vulgaris. J Clin Immunol. 2003, 23(4): 269-78.
114. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, Catron D, Buchanan ME, Muller A, deWaal Malefyt R, Deng G, Orozco R, Ruzicka T, Lehmann P, Lebecque S, Caux C, Zlotnik A. Up-regulation of macrophage inflammatory protein-3/CCL20 and CC chemokine receptor 6 in Psoriasisl. J Immunol. 2000, 164(12): 6621-6632.
115. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, Muller A, McClanahan TK, Dieu-Nosjean MC, Orozco R, Ruzicka T, Lehmann P, Oldham E, Zlotnik A. Cutting edge: the orphan chemokine receptor G protein-coupled receptor2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol. 2000, 164(7): 3465-3470.
I16. Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A, Mantovani A. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001, 107(9): 1173-1181.
117. Y. Teraki, A. Miyake, R. Takebayashi and T. Shiohara. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol. 2004, 29(6): 658-63.
118. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, Wong WH, Bowcock AM. Novel mechanisms of T cell and dendritic cell activation revealed by profiling of psoriasis on the 63, 100-element oligonucleotide array. Physiol Genomics. 2003, 13(1): 69-78.
119. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T cell priming and Th1/Th2-mediated responses. Immunol Today. 1998, 19(12): 568-574.
120. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science. 2000, 288(5466): 675-678.
121. Sallusto F, Elisabeth K, Belinda P, Andre H, Paul P, Shixin Q, Reinhold F, Martin L, Antonio L. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol. 1999. 29(6): 2037-2045.
122. Susan MK, Joyce TT, E John W, Bogumila TK, Charles DS, Rafi A. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003, 4(12): 1191-1198.
123. Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A, Ahmed R. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med. 2002, 195(12): 1541-1548.
124. Kieper WC, Tan JT, Bondi-Boyd B, Gapin L, Sprent J, Ceredig R. Surh CD. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J Exp Med. 2002, 195(12): 1533-1539.
125. Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J lmmunol. 168(10): 4827-4831.
126. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med. 2002, 195(12): 1523-1532.
127. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003, 3(4): 269-279.
128. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science. 1999, 286(5447): 2098-2102.
129. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002, 16(1): 1-4.
130. Bofill M, Almirall E, McQuaid A, Pena R, Ruiz-Hernandez R, Naranjo M, Ruiz L. Clotet B, Borras FE. Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA and CD45RO phenotype from tonsils, cord and adult peripheral blood. Clin Exp Immunol. 2004, 138(3): 460-465.
131. Christopherson KW, Hood AF, Travers JB, Ramsey H, Hromas RA. Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. Blood. 2003, 101(3): 801-806.
132. Yoshida R, Nagira M, Imai T, Baba M, Takagi S, Tabira Y, Akagi J, Nomiyama H, Yoshie O. EBIl-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC. Int Immunol. 1998, 10(7): 901-910.
133. Boisleve F, Kerdine-Romer S, Rougier-Larzat N, Pallardy M. Nickel and DNCB induce CCR7 expression on human dendritic cells through different signalling pathways: role of TNF-alpha and MAPK. J Invest Dermatol, 2004, 123(3): 494-502.
134. Rossi D, Zlotnik A. A biology of chemkined and their receptors. A Rev Immunol, 2000, 18: 217-242.135. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S. Briere F. Zlotnik A, Lebecque S, Caux C. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med, 1998, 188(2): 373-386.
136. Wamock RA, Campbell JJ, Doff ME, Matsuzawa A, McEvoy LM, Butcher EC. The role of chenmokines in the microenvironmental of control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med. 2000, 191 (1): 77-88.
137. Bradley LM, Watson SR, Swain SL. Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin. J Exp Med. 1994, 180(6): 2401-2406.
138. Schaerli P, Moser B. Chemokines: control of primary and memory T-cell traffic. Immunol Res. 2005, 31(1): 57-74.
139. Katou F, Ohtani H, Nakayama T, Nagura H, Yoshie O, Motegi K. Differential expression of CCL19 by DC-Lamp+ mature dendritic cells in human lymph node versus chronically inflamed skin. J Pathol. 2003, 199(1): 98-106.
140. Mackay CR. Dual personality of memory T cells. Nature. 1999, 401(6754): 659-660.
141. Randolph DA, Huang G, Carruthers CJ, Bromley LE, Chaplin DD. The role of CCR7 in TH1 and TH2 cell localization and delivery of B cell help in vivo. Science. 1999, 286(5447): 2159-2162.
142. Austin LM, Coven TR, Bhardwaj N, Steinman R, Krueger JG. Intra-epidermal lymphocytes in psoriatic lesions are activated GMP-17 (TIA-1)+CD8+CD3+CTLs as determined by phenotypic analysis. J Cutan Pathol. 1998, 125(2): 79-88.
143. Bovenschen HJ, Seyger MM, Van de Kerkhof PC. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol. 2005, 153(1): 72-78.
144. Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, van de Kerkhof PC. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol. 2004, 150(5): 852-859.
145. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res. 2000, 292(10): 519-521.
146. Pietrzak A, Lecewicz-Torun B, Rolinski J. Interleukin-18 serum concentration in patients with psoriasis triggered by infection. Ann Univ Mariae Curie Sklodowska. 2002, 57(2): 484-490.
147. Alam J, Cook JL. Reporter genes: application to the study of mammalian gene transcription. Anal Biochem. 1990, 188(2): 245-254.
148. Rincon M, Flavell RA, Davis RA. The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Radic Biol Med. 2000, 28(9): 1328-1337.
149. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch R J, Davis R J. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem. 1995, 270(13): 7420-7426.
150. Maulon L, Guerin S, Ricci JE, Breittmayer DF, Auberger P. T-Cell Receptor Signaling Pathway Exerts a Negative Control on Thrombin-Mediated Increase in [Ca2+] i and p38 MAPK Activation in Jurkat T Cells: Implication of the Tyrosine Kinase p56Lck. Blood. 1998, 91(11): 4232-4241.
151. Mathas S, Hinz M, Anagnostopoulos l, Krappmann D, Lietz A, Jundt F, Bomlnert K, Mechta-Grigoriou F, Stein H, Dorken B, Scheidereit C. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002, 21(15): 4104-4113.
2. Griffiths CE. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol. 2003, 17(Suppl 2): 1-5.
3. Zhang XJ, Zhang AP, Yang S, Gao M, Wei SC, He PP, Wang HY, Song YX, Cui Y, Chen JJ. Association of HLA class I alleles with psoriasis vulgaris in southeastern Chinese Hans. J Dermatol Sci. 2003, 33(1): 1-6.
4. Fatma OS, Sarper DA, Dilek E, Emel OA, Semra A, Dilek KS, Mahmut C. HLA-DRB1 association in Turkish psoriasis vulgaris patients. Swiss Med Wkly. 2003, 133(39-40): 541-543.
5. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004, 135(1): 1-8.
6. Lin WJ, Norris DA, Achziger M, Kotzin BL, Tomkinson B. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol. 2001, 117(6): 1546-1553.
7. Onuma S. Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J Dermatol. 1994, 21(4): 223-232.
8. The European FK506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind placebo-controlled study. Arch. Dermatol. 1996, 132(4): 419-423.
9. Servitje O, Bordas X, Seron D, Vidaller A, Moreno A, Curco N, Sais G, Peyri J. Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy. J Cutan Pathol. 1996, 23(5): 431-436.
10. Abu-Elmagd K, Van Thiel D, Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Thomson AW, Starzl TE. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc. 1991, 23(6): 3322-3324.
11. Morel P, Revillard J P, Nicolas J F, Wijdenes J, Rizova H, Thivolet J. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun. 1992, 5(4): 465-477.
12. Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GB, Solvsten H, Ibsen HH, Knudsen L, Jensen P, Petersen JH, Menne T, Baadsgaard O. HuMaxCD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol. 2003, 139(11): 1433-1439.
13. Gottlieb AB, Lebwohl M, Shirin S. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose. placebo-controlled study. J Am Acad Dermatol. 2000, 43(4): 595-604.
14. Chamian F, Lowes MA, Lin SL. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005, 102(6): 2075-2080.
15. Leonardi CL, Papp KA, Gordon KB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005, 52(3 Pt 1): 425-433.
16. Terry W, Barker J, Boehncke WH. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004, 151(Suppl 69): 3-17.
17. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, Plewig G. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol. 1994, 24(3): 593-598.
18. Bata CZ, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest. 1995, 95(1): 317-327.
19. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996, 98(8): 1878-1888.
20. Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AW, Tak PP, Bos JD, Teunissen MB. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res. 2004, 295(11): 465-473.
21. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003, 17(Suppl 2): 12-16.
22. Ellis CN, Krueger GG. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001, 345(4): 248-255.
23. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993, 101(5): 701-705.
24. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. T cells involved in psoriasis vulgaris belong to the Th 1 subset. J Invest Dermatol. 1994, 102(1): 145-149.
25. Romagnani S. Biology of human Th1 and Th2 cells. J Clin Immunol. 1995, 15(3): 21-129.
26. Dinarllo CA. IL-I: A Thl-inducing, Proinflammatory cytokine and new member of the IL-1 family. J AIlergy Clin lmmunol. 1999, 103(1 Pt 1): 11-24.
27. Puren A J, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFN- ν inducing factor) induces IL-1 13 and IL-8 via TNF-α production from non-CD14+ human blood mononuclear. J Clin Invest. 1998, 101(3): 711-721.
28. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995, 378 (6552): 88-91.
29. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H, Kurimoto M. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the bioligic activities of the protein. J Immunol. 1996, 156(11): 4274-4279.
30. Bazan JF, Timans J, Kastelein RA. A newly defined interleukin-1γ. Nature, 1996, 379(6566): 591-594.
31. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, Kurimoto M, Tanimoto T, Flavell RA, Sato V, t-larding MW, Livingston DJ, Su MS. Activation of interferon-gamma inlducing factor mediated by interleukin-lbeta converting enzyme. Science. 1997, 275(5297): 206-209.
32. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, Dinarello CA. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 1997, 386(6625): 619-623.
33. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T, Murakami T. Sanou O, Kojima H, Fujii M, Ohta T, Ikeda M, Ikegami H, Kurimoto M. Purification and characterization of the human interleukin-18 receptor. J Biol Chem. 1997, 272(41): 25737-25742.
34. Kim SH, Reznikov LL, Stuyt RJ, Selzman CH, Fantuzzi G, Hoshino T, Young HA, Dinarello CA. Functional reconstituution and regulation of IL-18 activity by the IL-18R beta chain. J lmmunol. 2001, 166(1): 148-154.
35. Gutzmer R, Langer K, Mommert S, Wittmann M, Kapp A, Werfel T. Human Dendritic Cells Express the IL-18R and Are Chemoattracted to IL-18. J Immunol. 2003, 171(12): 6363-6371.
36. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998, 161(7): 3400-3407.
37. Sareneva T, Julkunen I, Matikainen S. IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J Immunol. 2000, 165(4): 1933-1938.38. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit. AcPL, required for interleukin-18 signaling. J Biol Chem. 1998, 273(45): 29445-29450.
39. Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakanishi K, Takeda Y. Akira S. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 bianding receptor. J lmmunol. 1999. 162(9): 5041-5044.
40. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, Dinarello CA. Structural requirements of six naturally occurring isoforms of the IL-18 banding protein to inhibit IL-18. Proc Natl Acad Sci U S A. 2000, 97(3): 1190-1195.
41. Mee JB, Algm Y, Groves RW. Human keratinocytes constitutively produce but not process interleukin-18. Br J Dermatol. 2000, 143(2): 330-336.
42. Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, Caughman SW. Human keratinocytes constitutivelly express interleukin-18 and secrete biological active interleukin-18 afte treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Derrnatol. 1999, 113(5): 766-772.
43. Taniguchi M, Nagaoka K, Kunikata T, Kayano T, Yamauchi H, Nakamura S, Ikeda M, Orita K, Kurimoto M. Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. JPN J Cancer Res. 1998, 89(10): 1041-1046.
44. Taniguchi M, Nagaoka K, Kunikata T, Kayano T, Yamauchi H, Nakamura S. Ikeda M, Orita K, Kurimoto M. Characterization of anti-human interleukin-18 (IL-18)/interferon-gamma-inducing factor (IGIF) monoclonal antibodies and their application in the measurement of human IL-18 by ELISA. J Immunol Methods. 1997, 206(1-2): 107-113.
45. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murtine T helper 1 cells. Cell Immunol. 1996, 173(2): 230-235.
46. Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, Ikeda M, Kurimoto M. IFN-gamma-inducing factor (IGIF) is a costimulatory facto on the activation of Thl but not Th2 cells and exert its effect independently of IL-12. J Immunol. 1997, 158(4): 1541-1550.
47. Leung BP, Mclnnes IB, Esfandiari E, Wei XQ, Liew FY. Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol. 2000, 164(12): 6495-6502.
48. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Tht and Th2 responses, Annu Rev Immunol. 2001, 19: 423-474.
49. Rothe H, Hausmann A, Casteels K, Okamura H, Kurimoto M, Burkart V, Mathieu C, Kolb H. IL-18 inhibits diabetes development in nonobese diabetic mice by??counterregulation of Th1-dependent destructive insulitis. J Immunol. 1999. 163(3): 1230-1236.
50. Wild JS, Sigounas A, Sur N, Siddiqui MS, Alam R, Kurimoto M, Sur S. IFN-gamma-inducing factor (IL-18) inceases allergic sensitization, serum IgE. Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol. 2000, 164(5): 2701-2710.
51. Leite-De-Moraes MC, Hameg A, Pacilio M, Koezuka Y, Taniguchi M, Van Kaer L. Schneider E, Dy M, Herbelin A. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J Immunol. 2000, 166(2): 945-951.
52. Sugimoto T, Ishikawa Y, Yoshimoto T, Hayashi N, Fujimoto J, Nakanishi K. Interleukin 18 Acts on Memory T Helper Cells Type 1 to Induce Airway Inflammation and Hyperresponsiveness in a Naive Host Mouse. J Exp Med. 2004. 199(4): 535-545.
53. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000, 12(1): 59-63.
54. Koizumi H, Sato-Matsumura KC, Nakamura H, Shida K, Kikkawa S, Matsumoto M, Toyoshima K, Seya T. Distribution of IL-18 and IL-18 receptor in human skin: various forms of IL-18 are produced in keratinocytes. Arch Dermatol Res. 2001. 293(7): 325-333.
55. Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis. Arch Demeratol Res. 2001, 293(7): 334—342.
56. Pietrzak A, Lecewicz-Torun B, Chodorowska G, Rolinski J. Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score. Acta Derm Venereol. 2003, 83(4): 262-265.
57. Gangemi S, Merendino RA, Guarneri F, Minciullo PL, DiLorenzo G, Pacor M. Cannavo SP. Serum levels of interleukin-18 and s-ICAM-I in patients affected by psoriasis: Preliminary considerations. J Eur Acad Dermatol Venereol. 2003, 17(1): 42-46.
58. Wittmann M, Purwar R, Hartmann C, Gutzmer R, Werfel T. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. J Invest Dermatol. 2005, 124(6): 1225-1233.
59. Companjen A, van der Wel L, van der Fits L, Laman J, Prens E. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. Eur Cytokine Netw. 2004, 15(3): 210-216.
60. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18banding prptein: a novel modulator of the cytokine response. Immunity. 1999, 10(1): 127-136.61. Kojima H, Takeuchi M, Ohta T, Nishida Y, Arai N, Ikeda M, Ikegami H. Kurimoto M. IGIF does not drive Thl development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity. 1997, 7(4): 571-581.
62. Kojima H, Takeuchi M, Ohta T, Nishida Y, Arai N, Ikeda M, Ikegami H, Kurimoto M. Interleukin-18 activates the IRAK-TRAF6 pathway in mouse IL-14 cells. Biochem Biophys Res Commun. 1998, 244(1): 183-186.
63. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity. 1998, 9(1): 143-150.
64. Barbulescu K, Becker C, Schlaak JF, Schmitt E, Meyer zum Buschenfelde KH, Neurath MF. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Imnunol. 1998, 160(8): 3642-3647.
65. Shapiro L, Puren A J, Barton HA, Novick D, Peskind RL, Shenkar R, Gu Y, Su MS, Dinarello CA. Interleukin-18 stimulates production of human immunodeficiency virus in the U1 monocytic cell line. Proc Natl Acad Sci USA. 1998, 95(21): 12550-12555.
66. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000, 406(6797): 782-787.
67. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000, 343(5): 338-344.
68. Park H J, Kim H J, Lee JH, Lee JY, Cho BK, Kang JS, Kang H, Yang Y, Cho DH. Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. J Invest Dermatol. 2005, 124(4): 751-755.
69. Ariel A, Novick D, Rubinstein M, Dinarello CA, Lider O, Hershkoviz R. IL-12 and IL-18 induce MAP kinase-dependent adhesion of T cells to extracellular matrix components. J Leukoc Biol. 2002, 72(1): 192-198.
70. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 1999, 11 (11): 822-830.
71. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999, 401 (6754): 708-712.
72. Hagmann M. Memory T cells don't need practice. Science. 1999, 286(5443): 1267-1268.
73. Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science. 1999, 286(5443): 1377-1381.
74. Tough DF, Sun S, Zhang X, Sprent J. Stimulation of memory T cells by cytokines. Vaccine. 2000, 18(16): 1642-1648.75. Tanchot C, Rocha B. The organization of mature T-cell pools, Immunol Today. 1998, 19(12): 575-579.
76. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven Proliferation and Differentiation of Human Naive, Central Memory, and Effector Memory CD4+ T Cells. J Exp Med. 2001, 194(12): 1711-1720.
77. Kohout TA, Nicholas SL, Perry S J, Reinhart G, Junger S, Struthers RS. Differential desensitization, receptor phosphorylation, arrestin recruitment and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem. 2004, 279(22): 23214-23222.
78. Rollins BJ. Chemokines. Blood. 1997, 90(3): 909-928.
79. Murphy PM, Baggiolini M, Charo IF, Herbert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000, 52(2): 145-176.
80. James JC, Kristine EM, Eric JK, Christopher EB, Dulce S, Zhimin S, Judie B, Harry BG, Mark AV, Stuart BG, Mark CG, Andrew JW, Eugene CB, Lijun W. CCR7 Expression and Memory T Cell Diversity in Humans. J Immunol. 2001, 166(2): 877-884.
81. MacLennan IC, Gulbranson-Judge A, Toellner KM, Casamayor-Palleja M, Chan E, Sze DM, Luther SA, Orbea HA. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev. 1997, 156: 53-66.
82. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 1998, 281 (5373): 96-99.
83. Nanki T, Lipsky PE. Cytokine, activation marker, and chemokine receptor expression by individual CD4(+) memory T cells in rheumatoid arthritis synovium. Arthritis Res. 2000, 2(5): 415-423.
84. Von Andrian UH, Mackay CR. T cell function and migration. Two sides of the same coin. N Engl J Medical. 2000, 343(14): 1020-1034.
85. Campbell DJ, Debes GF, Johnston B, Wilson E, Butcher EC. Targeting T cell responses by selective chemokine receptor expression. Semin. Immunol. 2003, 15(5): 277-286.
86. Gudrun FD, Kerstin B, Thorsten W, Ute K, Stefan K, Thomas K, Alf H. CC chemokine receptor 7 expression by effector/memory CD4+ T Cells depends on antigen specificity and tissue localization during influenza a virus infection. J Virol. 78(14): 7528-7535.
87. Sebastiani S, Albanesi C, D'Pita O, Puddu P, Cavani A, Girolomoni G. The role chemokines in allergic contact dermatitis. Arch Dermatol Res. 2002, 293(11): 552-559.
88. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med. 1999, 189(3): 447-450.
89. Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai T, Yoshie O. Fractalkine (CX3CLI) as an amplification circuit of polarized Th1 responses. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem. 1998, 273(12): 7118-7122.
90. Nagira M, Imai T, Hieshima K, Kusuda J, Ridanpaa M, Takagi S, Nishimura M, Kakizaki M, Nomiyama H, Yoshie O. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13. J Biol Chem. 1997, 272(31): 19518-19524.
91. James CL, Robert KC, Youjin L, Hyung-Sik K, Yang W, Joel VW, Theresa B, Carl FW, Guido F, Yang-Xin F. Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J Clin Invest. 2003, 112(10): 1495-1505.
92. Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, Kitaura M, Nishimura M. Kakizaki M, Nomiyama H, Yoshie O. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem. 1997, 272(21): 13803-13809.
93. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA. 1998. 95(1): 258-263.
94. Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT. Nakano H. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med. 1999, 189(3): 451-460.
95. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999, 99(1): 23-33.
96. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol. 2002, 80(5): 497-505.
97. Noelia SS, Lorena RB, Gonzalo de la R, Amaya PK, Julio GB, Daniel M, Natividad L, Antonio C, Carlos C, Angel LC, Paloma SM, José Luis RF. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood. 2004, 104(3): 619-625.
98. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC, Laudanna C. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol. 1999, 162(5): 2472-2475.
99. Lars O, Mariette M, Niklas C, Gabriele H, Ziba K, (?) Z, Thomas B, Golo H. Reinhold F. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 2004, 21(2): 279-288.
100. Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, Lotze MT. Tahara H. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 2000, 60(8): 2209-2217.
101. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC, Laudanna C. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity. 2000, 13(6): 759-769.
102. Sallusto F, Mackay CF, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000, 18:593-620.
103. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Differential expression of chenmokine receptors and chemotactic responsiveness of type 1 T help cells (Thls) and Th2. J Exp Med. 1998, 187(1): 129-134.
104. D'Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Mantovani A. Sinigaglia F. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol. 1998, 161(10): 5111-5115.
105. Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, Girolomoni G. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune reponses. J Invest Dermatol. 2000, 114(2): 295-302.
106. Sebastiani S, Allavena P, Albanesi C, Nasorri F, Bianchi G, Traidl C, Sozzani S. Girolomoni G, Cavani A. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol. 2001, 116(2): 996-1002.
107. Sallusto F, Danielle L, Charles RM, Antonio L. Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes. J. Exp. Med. 1998, 187(6): 875-883.
108. Okada N, Mort N, Koretomo R, Okada Y, Nakayama T, Yoshie O, Mizuguchi H. Hayakawa T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005, 12(2): 129-139.
109. Chuntharapai A, Lee J, Hebert CA, Kim KJ. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol. 1994, 153(12): 5682-5688.
110. Beljaards RC, Van Beck P, Nieboer C, Stoof TJ, Boorsma DM. The expression of interleukin-8 receptor in untreated and treated psoriasis. Arch Dermatol Res. 1997, 289(8): 440-443.
111. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 2001, 81(3): 335-347.
112. Wakugawa M, Nakamura K, Kakinuma T, Onai N, Matsushima K, Tamak K: CC chemokine receptor 4 expression on peripheral blood CD4C T cells reflects disease activity of atopic dermatitis. J Invest Dermatol. 2001, 117(2): 188-196.
113. Makoto Inaoki, Shinichi Sato, Fumiaki Shirasaki, Naofumi Mukaida, Kazuhiko Takehara. The frequency of type 2 CD8+ T cells is increased in peripheral blood from patients with psoriasis vulgaris. J Clin Immunol. 2003, 23(4): 269-78.
114. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, Catron D, Buchanan ME, Muller A, deWaal Malefyt R, Deng G, Orozco R, Ruzicka T, Lehmann P, Lebecque S, Caux C, Zlotnik A. Up-regulation of macrophage inflammatory protein-3/CCL20 and CC chemokine receptor 6 in Psoriasisl. J Immunol. 2000, 164(12): 6621-6632.
115. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, Muller A, McClanahan TK, Dieu-Nosjean MC, Orozco R, Ruzicka T, Lehmann P, Oldham E, Zlotnik A. Cutting edge: the orphan chemokine receptor G protein-coupled receptor2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol. 2000, 164(7): 3465-3470.
I16. Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A, Mantovani A. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001, 107(9): 1173-1181.
117. Y. Teraki, A. Miyake, R. Takebayashi and T. Shiohara. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol. 2004, 29(6): 658-63.
118. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, Wong WH, Bowcock AM. Novel mechanisms of T cell and dendritic cell activation revealed by profiling of psoriasis on the 63, 100-element oligonucleotide array. Physiol Genomics. 2003, 13(1): 69-78.
119. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T cell priming and Th1/Th2-mediated responses. Immunol Today. 1998, 19(12): 568-574.
120. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science. 2000, 288(5466): 675-678.
121. Sallusto F, Elisabeth K, Belinda P, Andre H, Paul P, Shixin Q, Reinhold F, Martin L, Antonio L. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol. 1999. 29(6): 2037-2045.
122. Susan MK, Joyce TT, E John W, Bogumila TK, Charles DS, Rafi A. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003, 4(12): 1191-1198.
123. Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A, Ahmed R. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med. 2002, 195(12): 1541-1548.
124. Kieper WC, Tan JT, Bondi-Boyd B, Gapin L, Sprent J, Ceredig R. Surh CD. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J Exp Med. 2002, 195(12): 1533-1539.
125. Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J lmmunol. 168(10): 4827-4831.
126. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med. 2002, 195(12): 1523-1532.
127. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003, 3(4): 269-279.
128. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science. 1999, 286(5447): 2098-2102.
129. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002, 16(1): 1-4.
130. Bofill M, Almirall E, McQuaid A, Pena R, Ruiz-Hernandez R, Naranjo M, Ruiz L. Clotet B, Borras FE. Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA and CD45RO phenotype from tonsils, cord and adult peripheral blood. Clin Exp Immunol. 2004, 138(3): 460-465.
131. Christopherson KW, Hood AF, Travers JB, Ramsey H, Hromas RA. Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. Blood. 2003, 101(3): 801-806.
132. Yoshida R, Nagira M, Imai T, Baba M, Takagi S, Tabira Y, Akagi J, Nomiyama H, Yoshie O. EBIl-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC. Int Immunol. 1998, 10(7): 901-910.
133. Boisleve F, Kerdine-Romer S, Rougier-Larzat N, Pallardy M. Nickel and DNCB induce CCR7 expression on human dendritic cells through different signalling pathways: role of TNF-alpha and MAPK. J Invest Dermatol, 2004, 123(3): 494-502.
134. Rossi D, Zlotnik A. A biology of chemkined and their receptors. A Rev Immunol, 2000, 18: 217-242.135. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S. Briere F. Zlotnik A, Lebecque S, Caux C. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med, 1998, 188(2): 373-386.
136. Wamock RA, Campbell JJ, Doff ME, Matsuzawa A, McEvoy LM, Butcher EC. The role of chenmokines in the microenvironmental of control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med. 2000, 191 (1): 77-88.
137. Bradley LM, Watson SR, Swain SL. Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin. J Exp Med. 1994, 180(6): 2401-2406.
138. Schaerli P, Moser B. Chemokines: control of primary and memory T-cell traffic. Immunol Res. 2005, 31(1): 57-74.
139. Katou F, Ohtani H, Nakayama T, Nagura H, Yoshie O, Motegi K. Differential expression of CCL19 by DC-Lamp+ mature dendritic cells in human lymph node versus chronically inflamed skin. J Pathol. 2003, 199(1): 98-106.
140. Mackay CR. Dual personality of memory T cells. Nature. 1999, 401(6754): 659-660.
141. Randolph DA, Huang G, Carruthers CJ, Bromley LE, Chaplin DD. The role of CCR7 in TH1 and TH2 cell localization and delivery of B cell help in vivo. Science. 1999, 286(5447): 2159-2162.
142. Austin LM, Coven TR, Bhardwaj N, Steinman R, Krueger JG. Intra-epidermal lymphocytes in psoriatic lesions are activated GMP-17 (TIA-1)+CD8+CD3+CTLs as determined by phenotypic analysis. J Cutan Pathol. 1998, 125(2): 79-88.
143. Bovenschen HJ, Seyger MM, Van de Kerkhof PC. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol. 2005, 153(1): 72-78.
144. Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, van de Kerkhof PC. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol. 2004, 150(5): 852-859.
145. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res. 2000, 292(10): 519-521.
146. Pietrzak A, Lecewicz-Torun B, Rolinski J. Interleukin-18 serum concentration in patients with psoriasis triggered by infection. Ann Univ Mariae Curie Sklodowska. 2002, 57(2): 484-490.
147. Alam J, Cook JL. Reporter genes: application to the study of mammalian gene transcription. Anal Biochem. 1990, 188(2): 245-254.
148. Rincon M, Flavell RA, Davis RA. The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Radic Biol Med. 2000, 28(9): 1328-1337.
149. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch R J, Davis R J. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem. 1995, 270(13): 7420-7426.
150. Maulon L, Guerin S, Ricci JE, Breittmayer DF, Auberger P. T-Cell Receptor Signaling Pathway Exerts a Negative Control on Thrombin-Mediated Increase in [Ca2+] i and p38 MAPK Activation in Jurkat T Cells: Implication of the Tyrosine Kinase p56Lck. Blood. 1998, 91(11): 4232-4241.
151. Mathas S, Hinz M, Anagnostopoulos l, Krappmann D, Lietz A, Jundt F, Bomlnert K, Mechta-Grigoriou F, Stein H, Dorken B, Scheidereit C. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002, 21(15): 4104-4113.